135 related articles for article (PubMed ID: 33843428)
41. Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway.
Jin Y; Xu L; Wu X; Feng J; Shu M; Gu H; Gao G; Zhang J; Dong B; Chen X
Oncol Res; 2019 Jun; 27(6):729-737. PubMed ID: 30837032
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of the novel tubulin polymerization inhibitor PTC-028 for myelodysplastic syndrome.
Zhong C; Kayamori K; Koide S; Shinoda D; Oshima M; Nakajima-Takagi Y; Nagai Y; Mimura N; Sakaida E; Yamazaki S; Iwano S; Miyawaki A; Ito R; Tohyama K; Yamaguchi K; Furukawa Y; Lennox W; Sheedy J; Weetall M; Iwama A
Cancer Sci; 2020 Dec; 111(12):4336-4347. PubMed ID: 33037737
[TBL] [Abstract][Full Text] [Related]
43. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T; Chinen T; Nishiyama A; Asada S; Shimura R; Isobe T; Yamamoto K; Sato N; Enomoto Y; Tanaka Y; Fukuyama T; Satoh H; Kato K; Saitoh K; Ishikawa T; Soga T; Nannya Y; Fukagawa T; Nakanishi M; Kitagawa D; Kitamura T; Goyama S
Cell Rep; 2023 Sep; 42(9):113098. PubMed ID: 37714156
[TBL] [Abstract][Full Text] [Related]
44. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
[TBL] [Abstract][Full Text] [Related]
45. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
[TBL] [Abstract][Full Text] [Related]
46. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.
Daskalakis M; Nguyen TT; Nguyen C; Guldberg P; Köhler G; Wijermans P; Jones PA; Lübbert M
Blood; 2002 Oct; 100(8):2957-64. PubMed ID: 12351408
[TBL] [Abstract][Full Text] [Related]
47. The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia.
Soncini M; Santoro F; Gutierrez A; Frigè G; Romanenghi M; Botrugno OA; Pallavicini I; Pelicci P; Di Croce L; Minucci S
Biochim Biophys Acta; 2013 Jan; 1832(1):114-20. PubMed ID: 23046813
[TBL] [Abstract][Full Text] [Related]
48. Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells
Wang Z; Wang Z; Li S; Li B; Sun L; Li H; Lin P; Wang S; Teng W; Zhou X; Ye Z
Front Immunol; 2018; 9():1239. PubMed ID: 29910819
[TBL] [Abstract][Full Text] [Related]
49. Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects.
Ureshino H; Kurahashi Y; Watanabe T; Yamashita S; Kamachi K; Yamamoto Y; Fukuda-Kurahashi Y; Yoshida-Sakai N; Hattori N; Hayashi Y; Kawaguchi A; Tohyama K; Okada S; Harada H; Ushijima T; Kimura S
Mol Cancer Ther; 2021 Aug; 20(8):1412-1421. PubMed ID: 34045225
[TBL] [Abstract][Full Text] [Related]
50. Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation.
Si J; Boumber YA; Shu J; Qin T; Ahmed S; He R; Jelinek J; Issa JP
Cancer Res; 2010 Sep; 70(17):6968-77. PubMed ID: 20713525
[TBL] [Abstract][Full Text] [Related]
51. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
Link PA; Baer MR; James SR; Jones DA; Karpf AR
Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
[TBL] [Abstract][Full Text] [Related]
52. Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome.
Zhao WH; Zeng QC; Huang BT; Li BS; Chen RL
Leuk Res; 2015 Apr; 39(4):424-8. PubMed ID: 25721158
[TBL] [Abstract][Full Text] [Related]
53. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
[TBL] [Abstract][Full Text] [Related]
54. Prolonged treatment with DNMT inhibitors induces distinct effects in promoters and gene-bodies.
Wong YF; Jakt LM; Nishikawa S
PLoS One; 2013; 8(8):e71099. PubMed ID: 23940695
[TBL] [Abstract][Full Text] [Related]
55. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).
DeZern AE; Zeidan AM; Barnard J; Hand W; Al Ali N; Brown F; Zimmerman C; Roboz GJ; Garcia-Manero G; Steensma DP; Komrokji RS; Sekeres MA;
Leuk Lymphoma; 2017 Jun; 58(6):1325-1331. PubMed ID: 27774847
[TBL] [Abstract][Full Text] [Related]
56. [Effect of decitabine combined with Trichostatin A on MDS cell line SKM-1 in vitro].
Yang L; Xu RR; Song GQ; Hang HM; Liu H; Jiang SH; Wang XF; Ding XS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):819-23. PubMed ID: 18718068
[TBL] [Abstract][Full Text] [Related]
57. TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
Chang CK; Zhao YS; Xu F; Guo J; Zhang Z; He Q; Wu D; Wu LY; Su JY; Song LX; Xiao C; Li X
Br J Haematol; 2017 Feb; 176(4):600-608. PubMed ID: 27984642
[TBL] [Abstract][Full Text] [Related]
58. Azacytidine causes complex DNA methylation responses in myeloid leukemia.
Stresemann C; Bokelmann I; Mahlknecht U; Lyko F
Mol Cancer Ther; 2008 Sep; 7(9):2998-3005. PubMed ID: 18790780
[TBL] [Abstract][Full Text] [Related]
59. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
60. Decitabine Inhibits Gamma Delta T Cell Cytotoxicity by Promoting KIR2DL2/3 Expression.
Niu C; Li M; Zhu S; Chen Y; Zhou L; Xu D; Li W; Cui J; Liu Y; Chen J
Front Immunol; 2018; 9():617. PubMed ID: 29632540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
